Global Aerosol Delivery Devices Market Worth USD 59252 Million By 2031 | CAGR of 5.08%

Introduction

Inhalable aerosols are a convenient way to administer medications. Asthma and chronic obstructive pulmonary disease are only two examples of respiratory and non-respiratory disorders that are often treated or prevented with inhaled medication. The use of an aerosol delivery method has numerous advantages, such as the rapid onset of action of broncho-active drugs, the convenience of patient self-administration, and the direct deposition of inhaled medication at airway receptor sites. Substantial market expansion for the DPI subsegment throughout the forecast period may be attributed to rising demand for DPI, rising patient awareness of the need for effective and enhanced respiratory equipment, technological developments in DPI medicine delivery, and the introduction of cost-efficient solutions.

Market Dynamics

Increase in Air Pollution Drives the Global Market

Increased air pollution from sources like vehicle emissions and human activity are primarily to blame for spreading respiratory diseases like COPD and asthma. Many studies have shown that breathing dirty air might exacerbate asthma symptoms. Both ozone (found in smog) and particulate matter (found in smoke, haze, and dust) are major air pollutants that can severely aggravate asthma symptoms. Increasing ozone and particle matter levels creates a heightened risk of asthma attacks. Market growth is expected to be spurred by the anticipated increase in asthma and chronic obstructive pulmonary disease (COPD) cases due to rising levels of air pollution.

Growth opportunities in emerging markets Create Tremendous Opportunities

Opportunities in emerging economies are expected to fuel growth in the aerosol delivery devices market due to rising rates of chronic obstructive pulmonary disease, smoking, and chemical exposure due to urbanization. The healthcare industries of emerging nations are growing due to rising demand for advanced technological manufacturing systems and large government expenditures aimed at improving healthcare infrastructure. Also, the pharmaceutical and medical device sectors in China and India, two of the fastest-growing economies, are thriving and offer significant opportunities for market expansion.

Regional Analysis

North America is the most significant shareholder in the global aerosol delivery market. The three most influential countries in North America—the USA, Canada, and Mexico—are all discussed in the paper. The United States brought in the most cash among the North American countries. More effort is being put into R&D; goods like VR647, LIQ861, and APC-4000 are in various stages of development for the pipeline, and state-of-the-art resources are easily accessible. Aerosol delivery devices, the availability of generous reimbursement policies, the increasing awareness of the benefits these products offer in healthcare, and the presence of a substantial older population all contribute to the market's growth.

Europe is expected to grow during the forecast period. The growing demand for cutting-edge aerosol delivery devices, together with the dominance of firms such as GlaxoSmithKline plc and Koninklijke Philips N.V., bodes well for the European aerosol delivery devices market in the future. Growing demand for aerosol delivery devices among patients in Europe is helping the industry grow, as is the EAACI's work to increase public understanding of asthma, COPD, and other respiratory disorders. Significant growth factors in Europe include the increasing prevalence of respiratory illnesses and the launch of innovative pharmaceutical and medical device innovations.

Asia and the Pacific, including Japan, China, India, Australia, South Korea, and the rest of the region, are considered. The aging population and the rising number of smokers fuel the market's growth in this sector. According to the World Health Organization, about 90% of deaths from COPD and asthma occur in low- and middle-income countries. The rising demand for inhalers, nebulizers, and other home healthcare devices is a significant factor in the development of this sector. As a result, the low cost of medical equipment and the rising public knowledge of the use and benefits of these devices are the fundamental causes for the significant expansion of the industry.

Key Highlights

• The global aerosol delivery devices market was valued at USD 37934 million in 2022. It is projected to reach USD 59252 million by 2031, growing at a CAGR of 5.08% during the forecast period (2023–2031).
• Based on product, the global aerosol delivery devices market is bifurcated into dry powder inhalers, metered dose inhalers, and nebulizers. The metered dose inhalers segment is the highest contributor to the market.
• Based on application, the global aerosol delivery devices market is bifurcated into asthma, chronic obstructive pulmonary disease, cystic fibrosis, and non-respiratory diseases. The asthma segment is the highest contributor to the market.
• Based on distribution channels, the global aerosol delivery devices market is bifurcated into retail pharmacies, hospital pharmacies, and e-commerce. The retail pharmacies segment is the highest contributor to the market.
• North America is the most significant shareholder in the global aerosol delivery

Competitive Players

Competitive Players

The global aerosol delivery devices market’s major key players are 3M Company, Aerogen, GlaxoSmithKline plc, Johnson & Johnson, Vectura Group plc, Koninklijke Philips N.V., Merck & Co. Inc., Metall Zug AG, Recipharm AB, and Teva Pharmaceutical Industries Ltd.

Recent Developments

Market News

• In October 2022, GSK announced a new partnership with Tempus to increase its R&D output in the field of precision medicine.
• In December 2022, Recipharm announced that it would increase its commercial production of Talicia® to help RedHill Biopharma.

Segmentation

Global Aerosol Delivery Devices Market: Segmentation

By Product

• Dry powder inhalers
• Metered dose inhalers
• Nebulizers

By Application

• Asthma
• Chronic obstructive pulmonary disease
• Cystic fibrosis
• Non respiratory diseases

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• E-commerce

By Regions

• North America
• Europe
• Asia-Pacific
• LAMEA